CVRx, Inc. Common Stock
CVRXCVRx, Inc. is a medical device company specializing in the development of implantable neuromodulation therapies designed to treat chronic heart failure and hypertension. The company's flagship product, the Barostim Therapy, aims to restore healthy autonomic nervous system balance by stimulating the carotid baroreceptors, potentially improving symptoms and outcomes for patients with these conditions.
Company News
CVRx's Barostim device has demonstrated significant reductions in hospital visits and length of stay for heart failure patients, according to new real-world evidence presented at the THT 2025 conference and published in the Journal of Cardiac Failure.
CVRx, a medical device company, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company's Barostim System, which uses neuromodulation to improve heart failure symptoms, has received FDA approval and the CE Mark in the European Economic Area.
Masimo's shares surged 8.7% after the company's newly elected Board of Directors, proposed by activist investor Quentin Koffey, won election to the two available Board seats. Investors view this as a positive development, expecting the new Board to be more responsive to shareholders.
Bragar Eagel & Squire, P.C. is investigating potential securities law violations by Arhaus, Cardlytics, and CVRx. The investigations focus on issues related to financial reporting, CEO departures, and reimbursement changes.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of CVRx, Inc. (CVRX) investors after the Centers for Medicare and Medicaid Services proposed payment rate cuts for CVRx's heart failure device, causing a significant drop in the company's stock price.
